En vivo
Endpoints NewsLack of specifics on obesity pill sales hover over Lilly’s first quarterEndpoints NewsThe R&D 15: How pharma's top companies spent, won and lost on drug researchEndpoints NewsNovartis unveils North Carolina factory as final new build in $23B US expansionFierceBiotechGSK’s $700M Alector bet blows up as Alzheimer’s drug flunks phase 2FierceBiotechAvalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugsFierceBiotechAstraZeneca plucks preclinical EGFR degrader from Pinetree for $25MNovo NordiskIs Novo Nordisk's GLP-1 dominance fading after Lilly's clinical wins? - MSNSiemens HealthineersSiemens Healthineers: A €6 Billion Diagnostics Exit and a Coming Spin-Off as Shares Hit Rock Botto - AD HOC NEWSBioPharma DiveAvalyn, in pursuit of better lung drugs, banks $300M in an IPOSinopharm Chemical Reagent Co., Ltd.Stabilizers Price in China - Market Insights - IndexBoxeLifeThe FAM53C/DYRK1A axis regulates the G1/S transition of the cell cycleInsilico MedicineInsilico Medicine Secures IND Clearance For Rentosertib Inhalation Solution To Advance Targeted IPF Therapy - BioPharma APAC
C.GERHARDT 10 feb 2024

PERICYTES AS TARGETS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA - Frontiers

PERICYTES AS TARGETS IN HEREDITARY HEMORRHAGIC TELANGIECTASIA - Frontiers

Original
Contenido no disponible. Consulta la fuente original.